Elizabeth McKenna: New Cancer Grand Challenges Teams Announced / OncoDaily
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
#healthcare #biotech #drugdevelopment #oncology #healthcarefinance #cancerresearch #researchfunding
Saturday, March 7, 2026, 11:22 am / permalink 20326 / 67 stories in 3 days
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS / OncoDaily
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Saturday, March 7, 2026, 9:22 am / permalink 20321 / 3 stories in 4 days
New FDA bonus pilot to address 'workforce challenges' / Endpoints
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
#healthcare #pharmaceuticals #governmentpolicy #biotech #drugdevelopment #fda #healthcarefinance
Saturday, March 7, 2026, 12:23 am / permalink 20312 / 2 stories in 4 days
FDA lifts hold on Intellia trial / Beckers
Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Saturday, March 7, 2026, 12:23 am / permalink 20309 / 2 stories in 4 days
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology / MedCity
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #healthcarefinance #infectiousdisease
Saturday, March 7, 2026, 12:22 am / permalink 20307 / 3 stories in 4 days
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma / MedCity
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #healthcarefinance
Saturday, March 7, 2026, 12:22 am / permalink 20306 / 4 stories in 4 days